2025-046: Histone Acetylation Blood Biomarker for Alzheimer’s Disease
Benefit
This technology introduces a fundamentally new diagnostic class: a blood-based assay that measures epigenetic enhancer activation rather than downstream neuronal damage. It enables clinicians and researchers to detect Alzheimer’s disease at its earliest molecular stage, years before symptoms or protein aggregation occur. A biomarker assay based on this technology provides a mechanistic, cost-effective, and scalable solution for early diagnosis, therapeutic monitoring, and patient stratification. Importantly, it would present a shift in Alzheimer's detection. By understanding the disease's origin at the epigenomic level, the approach moves from simply reacting to symptoms to proactively predicting the disease.
Market Application
- Early and differential diagnosis of Alzheimer’s disease
- Patient stratification and therapeutic response monitoring in clinical trials
- Laboratory-developed tests (LDTs) and CLIA-certified diagnostic panels
- Companion diagnostics for drugs targeting epigenetic or neuroinflammatory pathways
- Expansion to other neurodegenerative and psychiatric disorder driven by enhancer dysregulation
Publications
NA